Companies › Wellizen Australia
1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Theronomic Ova-All Care Tribiotic (prebiotic, probiotic, postbiotic) regulating gut microbiome to affect estrogen | – | Phase 2 | Polycystic Ovarian Syndrome (PCOS) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06963840 | Theronomic Ova-All Care | Phase 2 | Polycystic Ovarian Syndrome (PCOS) | Metabolic and endocrine | Aug 2025 |
No annotated target.
–
Estar Medical dba Medical Technologies AB Biotics Immunis Spur Therapeutics iECURE
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.